Fertility Decoded

IVF add-ons: what the evidence says before you pay extra

IVF add-ons are extra tests and treatments offered on top of a standard cycle, often for a significant extra fee, and often after a failed cycle. The honest summary is that for most add-ons there is little or no good evidence they improve your chance of a baby. The UK regulator's expert review of common add-ons rated none of them as clearly effective. This guide explains the main add-ons, what the evidence shows, and the questions to ask so you can decide with clear eyes rather than under pressure.

An IVF add-on is any extra test, procedure, or medicine offered on top of a standard cycle, usually for an additional fee. They are most often suggested to people who have had a cycle fail, when the wish to "do everything possible" is strongest and hardest to argue with.

Here is the uncomfortable but useful truth: for most add-ons, there is little or no reliable evidence that they raise your chance of a baby. When the UK fertility regulator (the HFEA) and its expert panel reviewed the common add-ons, not one met the bar for clear evidence of benefit. That does not make every add-on worthless for every person, but it does mean an add-on should be a careful, informed choice, not a default.

The common add-ons, and what the evidence shows

Add-onWhat it claimsWhat the evidence says
Endometrial receptivity test (ERA)Finds your personal 'window' for transferRated poorly; trials do not show it improves live-birth rates for most patients
Immune testing and treatments (e.g. NK cells, steroids, intralipids)Treats the immune system to help implantationUnclear and not established; not supported for routine use, and some treatments carry their own risks
Endometrial scratchA small scratch to help the embryo implantWeak or conflicting evidence; large trials show no clear benefit
Assisted hatchingThins the embryo's shell to aid implantationUnclear; no consistent benefit for most patients
Time-lapse imaging / embryo glueBetter embryo selection or implantationUnclear or limited; not shown to reliably raise live-birth rates
PGT-A (genetic screening of embryos)Selects chromosomally normal embryosHelps in specific situations, but does not improve overall live-birth rates for everyone; a real decision with trade-offs

The pattern across the list is consistent: a plausible-sounding rationale, real cost, and evidence that is either weak, conflicting, or absent for the average patient. PGT-A is the most nuanced case, with genuine uses in particular circumstances, which is why it has its own fuller page.

Why add-ons get sold anyway

Understanding the incentives helps you stay steady. After a failed cycle, both you and the clinic want to change something, and an add-on is a concrete thing to offer. Add-ons are also a source of revenue. Neither of these is evidence that a given add-on works. The question is never "would I try anything?" but "does this specific thing have evidence behind it for someone like me?"

Questions to ask before agreeing to any add-on

  • What is the evidence that this improves my chance of a live birth, specifically?
  • How much does it cost, and is that on top of the cycle price?
  • What is the actual size of the benefit you expect for me, and why?
  • Are there any risks or downsides to doing it?
  • What would you advise if cost were not a factor, and what if it were?

Cost matters especially where cycles are paid for out of pocket, as most are in India. Money spent on unproven add-ons is money not available for another full cycle, and a further cycle often does more for your cumulative chance of a baby than an add-on does. If you are weighing a second attempt, the page on trying again looks at what is actually worth changing.

My clinic says an add-on will improve my chances. Should I believe them?
Ask them to show you the evidence for a live-birth benefit in someone like you, and the size of that benefit. For most add-ons the reliable evidence is weak or absent, and the UK regulator's expert review rated none of the common ones as clearly effective. A good clinic will discuss this openly rather than present add-ons as routine.
Is PGT-A the same as the other add-ons?
It is more nuanced. PGT-A screens embryos for chromosome problems and has genuine uses in specific situations, but it does not raise overall live-birth rates for everyone and carries cost and trade-offs. It deserves a specific conversation about your situation rather than a blanket yes or no.
If add-ons mostly lack evidence, why are they offered?
Partly because after a setback everyone wants to change something, and an add-on is a tangible option. Partly because they generate revenue. Neither reason is evidence that a particular add-on works, which is why the specific-evidence question matters.
Is it wrong to try an add-on anyway?
Not necessarily, if you go in with clear eyes: you understand the evidence is weak, you know the cost, and you have weighed it against putting that money toward another full cycle. The problem is not choice; it is being sold an add-on as routine or as the reason a cycle failed.

Related

Last updated .